{
    "nct_id": "NCT03638141",
    "official_title": "The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab",
    "inclusion_criteria": "* Signed informed consent form\n* Age ≥18 years.\n* Newly diagnosed with hepatocellular carcinoma\n* Have measurable disease\n* Have disease that responds to DEB-TACE\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Body weight >30 kg\n* Evidence of clinical or radiographic ascites with a score < 7\n* Patients must have adequate organ function defined by study-specified laboratory tests.\n* Evidence of post-menopausal status or negative pregnancy test\n* Willing and able to comply with study procedures\n* Willing to undergo a liver biopsy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Anyone involved with the planning and/or conduct of the study.\n* Has participated in another investigational study during the last 6 months.\n* Any concurrent anticancer therapy or received therapy ≤30 days prior to study.\n* Major surgical procedure at the time of study enrollment or within 28 days prior to the first dose of IP.\n* Have a diffuse HCC (Hepatocellular Carcinoma), vascular invasion or extrahepatic tumor.\n* Main portal vein thrombosis present on imaging.\n* History of hepatic encephalopathy within past 12 months or require medications to prevent or control encephalopathy.\n* Ascites within 6 weeks prior to study treatment.\n* Any contraindications for embolization.\n* Has an active infection such as TB, HIV, hepatitis B or C.\n* History of another primary malignancy.\n* History of leptomeningeal carcinomatosis.\n* History of active primary immunodeficiency.\n* Any unresolved toxicities from previous anticancer therapy.\n* Grade ≥2 neuropathy.\n* History of bleeding disorder.\n* History or current use of immunosuppressive medications within 14 days prior to study medications.\n* Has an active known or suspected autoimmune disease.\n* Patients with hypothyroidism.\n* Any active skin conditions.\n* History of allogenic organ transplantation.\n* Significant heart disease.\n* Patients weighing < 30 kg.\n* Patients with celiac disease not controlled by diet alone.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Have received a live vaccine within 30 days prior to study drug.\n* Woman who are pregnant or breastfeeding.\n* Known allergy or hypersensitivity to the study drug.\n* Have received durvalumab, tremelimumab, anti-PD-1, anti-PD-L1 or anti-CTLA-4 in a prior study.\n* Unwilling or unable to follow the study schedule for any reason.",
    "miscellaneous_criteria": ""
}